CohBar IDs Peptide to Advance in Testing as Possible IPF Treatment

CohBar IDs Peptide to Advance in Testing as Possible IPF Treatment

CohBar has chosen CB5138-3 as its lead treatment candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, based on its promising safety, efficacy, and drug-like properties in preclinical studies. The company is planning to further test this peptide — a small protein fragment — in early studies…

Peptide-coated Nanoparticles Limit Damage of IPF, Early Study Finds

Tiny particles, or nanoparticles, coated with a peptide called GSE4 prevented some features of idiopathic pulmonary fibrosis (IPF) and eased others in a rat model of this disease, scientists report. No harmful effects were associated with the use of these GSE4-loaded nanoparticles in the animals, the team added, suggesting they should…